IndustryCompany release
Emmaus Q3 revenue falls to $1.9M after Endari licence; going-concern doubt flagged
🇺🇸 Emmaus Life Sciences, Inc. (EMMA) · Thu 19 Nov 2026
Emmaus Life Sciences reports a wider third-quarter net loss of $4.7M and $1.0M in cash, as its May licence deal with NeoImmuneTech moved Endari sales away from the company.
Emmaus Life Sciences reported results for the quarter ended 30 September 2026 on 18 November. Net revenue fell to $1.9M, down from $3.4M in the same quarter a year earlier.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Emmaus Life Sciences, Inc. ↗
Article written by VigiEye from the official source (Emmaus Life Sciences, Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
CytoSorbents reaches operating cash flow breakeven in Q3 as operating loss narrows 59%
🇺🇸 Cytosorbents Corp (CTSO) · Thu 19 Nov 2026
Prenetics widens H2 EBITDA loss guidance to $30-35M as IM8 spending rises
Prenetics Global Ltd (PRE) · Wed 18 Nov 2026
Quantum-Si detects all 20 amino acids at single-molecule level on Proteus platform
🇺🇸 Quantum-Si Inc (QSI) · Wed 18 Nov 2026
NeOnc to meet FDA in January 2027 on NEO100 accelerated approval path
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Wed 18 Nov 2026
newcleo reports Q3 revenue of about €10M and €233.4M cash as PRECURSOR e-core completed
newcleo plc (NWCL) · Wed 18 Nov 2026
Iridex cuts 2026 revenue guidance to $46-48M after 19% third-quarter sales drop
🇺🇸 Iridex Corp (IRIX) · Tue 17 Nov 2026